159992 创新药
已收盘 07-22 15:00:00
资讯
新帖
简况
国产创新药获批成果丰硕，创新药ETF易方达（516080）连续7日获资金加仓
证券之星 · 07-22 19:37
国产创新药获批成果丰硕，创新药ETF易方达（516080）连续7日获资金加仓
恩华药业：公司创新药NH600001处于CDE正常审核之中
证券之星 · 07-22 16:33
恩华药业：公司创新药NH600001处于CDE正常审核之中
聚焦四川上市公司 | 商业化兑现期来临，创新药迎来产业转折点 这些上市川企估值有望获得提升
金融投资网 · 07-22 16:32
聚焦四川上市公司 | 商业化兑现期来临，创新药迎来产业转折点 这些上市川企估值有望获得提升
研报掘金丨华源证券：首予众生药业“买入”评级，进入创新药价值兑现关键阶段
格隆汇 · 07-22 14:34
研报掘金丨华源证券：首予众生药业“买入”评级，进入创新药价值兑现关键阶段
英硅智能(03696)最高涨8% AI创新药龙头迎来板块情绪催化
金吾财讯 · 07-22 14:05
英硅智能(03696)最高涨8% AI创新药龙头迎来板块情绪催化
创新药板块早盘冲高回落，港股通创新药ETF易方达（159316）连续4日“吸金”累计超3.5亿元
证券之星 · 07-22 13:08
创新药板块早盘冲高回落，港股通创新药ETF易方达（159316）连续4日“吸金”累计超3.5亿元
创新药主题基金总规模突破1500亿元；张坤最新调仓动向曝光
每日经济新闻 · 07-22 08:01
创新药主题基金总规模突破1500亿元；张坤最新调仓动向曝光
沃华医药：目前暂未有创新药项目
证券之星 · 07-21 20:51
沃华医药：目前暂未有创新药项目
公司问答丨海南海药：创新药氟非尼酮III期已制定研发进度计划 目前已开始III期临床相关前期工作 派恩加滨IIb期正积极推进
格隆汇 · 07-21 17:40
公司问答丨海南海药：创新药氟非尼酮III期已制定研发进度计划 目前已开始III期临床相关前期工作 派恩加滨IIb期正积极推进
葛兰旗下中欧医疗健康混合二季报：君实生物(688180.SH)新进十大重仓 创新药及产业链仍是布局主要方向
智通财经 · 07-21 17:16
葛兰旗下中欧医疗健康混合二季报：君实生物(688180.SH)新进十大重仓 创新药及产业链仍是布局主要方向
又下一城！鸿鹄航空构建创新药全球温控中国方案
证券之星 · 07-21 14:40
又下一城！鸿鹄航空构建创新药全球温控中国方案
创新药物销售强劲抵消仿制药冲击！诺华制药Q2业绩超预期 释放重回增长轨道信号
智通财经 · 07-21 14:28
创新药物销售强劲抵消仿制药冲击！诺华制药Q2业绩超预期 释放重回增长轨道信号
出海爆发+投融资回暖+业绩预增！恒生创新药ETF华泰柏瑞（520500）T+0助力把握低估值创新药反弹机遇
新浪基金 · 07-21 13:43
出海爆发+投融资回暖+业绩预增！恒生创新药ETF华泰柏瑞（520500）T+0助力把握低估值创新药反弹机遇
Halozyme(HALO)与Incyte(INCY)联合推进创新药INCA033989皮下注射剂型开发
金吾财讯 · 07-20 20:59
Halozyme(HALO)与Incyte(INCY)联合推进创新药INCA033989皮下注射剂型开发
睿远成长价值混合基金披露二季报：减持PCB、芯片和光通信板块 港股配置以消费和创新药为主
智通财经 · 07-20 20:22
睿远成长价值混合基金披露二季报：减持PCB、芯片和光通信板块 港股配置以消费和创新药为主
创新药板块走强，半导体板块延续调整，科创50ETF易方达（588080）近5日“吸金”超30亿元
证券之星 · 07-20 20:18
创新药板块走强，半导体板块延续调整，科创50ETF易方达（588080）近5日“吸金”超30亿元
创新药火速修复，520880成反弹急先锋！场内唯一药ETF8天7涨！映恩生物、艾力斯、荣昌生物等多股释放利好
新浪基金 · 07-20 19:19
创新药火速修复，520880成反弹急先锋！场内唯一药ETF8天7涨！映恩生物、艾力斯、荣昌生物等多股释放利好
申联生物：在研创新药具备差异化竞争优势
证券之星 · 07-20 16:48
申联生物：在研创新药具备差异化竞争优势
创新药板块活跃 荣昌生物(09995)涨7.28% 多支头部公募大举举牌港股创新药
金吾财讯 · 07-20 10:26
创新药板块活跃 荣昌生物(09995)涨7.28% 多支头部公募大举举牌港股创新药
基金忠言｜富国和易方达双双出手，捕捉创新药大牛股
蓝鲸财经 · 07-20 10:18
基金忠言｜富国和易方达双双出手，捕捉创新药大牛股
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.88,"timestamp":1784703792000,"preClose":0.879,"halted":0,"volume":1551930948,"delay":0,"changeRate":0.0011,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":0.001,"latestTime":"07-22 15:00:00","open":0.874,"high":0.904,"low":0.866,"amount":1377000000,"amplitude":0.0432,"askPrice":0.881,"askSize":39730,"bidPrice":0.88,"bidSize":29979,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784770200000},"marketStatusCode":5,"adr":0,"adjPreClose":0.879,"symbolType":"fund","openAndCloseTimeList":[[1784683800000,1784691000000],[1784696400000,1784703600000]],"highLimit":0.967,"lowLimit":0.791,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.192766,"marketValue":0,"turnoverRate":0,"status":0,"floatMarketCap":0},"requestUrl":"/m/hq/s/159992","defaultTab":"news","newsList":[{"id":"2653520867","title":"国产创新药获批成果丰硕，创新药ETF易方达（516080）连续7日获资金加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2653520867","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653520867?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:37","pubTimestamp":1784720231,"startTime":"0","endTime":"0","summary":"截至收盘，恒生港股通创新药指数上涨1.2%，中证港股通医药卫生综合指数上涨0.5%，中证创新药产业指数上涨0.2%，中证生物科技主题指数下跌0.1%，沪深300医药卫生指数上涨0.5%。同花顺iFinD数据显示，截至昨日，创新药ETF易方达已连续7日获资金净流入，合计约6.7亿元。工信部表示，今年上半年，38款创新药获批上市，其中国产创新药31款，占比超过80%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026072200042496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["516080","159992","BK1161","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653816753","title":"恩华药业：公司创新药NH600001处于CDE正常审核之中","url":"https://stock-news.laohu8.com/highlight/detail?id=2653816753","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653816753?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:33","pubTimestamp":1784709195,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业07月22日在投资者关系平台上答复投资者关心的问题。今天是7月21日，新药NH600001在6月8日六灯全灭的，到现在第30个工作日了，据说CDE结尾审批超过30个工作日属于重度超时。麻烦问一下，1、NH600001CDE审批环节是否一切顺利，有没有可能重度超时。恩华药业回复：公司创新药NH600001处于CDE正常审核之中，各项相关工作在有序顺利进行。获得该创新药上市批件后，公司会及时进行公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200033623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","LU2148510915.USD","BK1161","159992","LU1064130708.USD","BK0239","002262","BK0188","BK0070","LU1064131003.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653753587","title":"聚焦四川上市公司 | 商业化兑现期来临，创新药迎来产业转折点 这些上市川企估值有望获得提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2653753587","media":"金融投资网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653753587?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:32","pubTimestamp":1784709124,"startTime":"0","endTime":"0","summary":"我国创新药行业正迎来关键转折，从过去重投入的研发蓄力期，大步迈入商业化兑现与回报收获期，企业盈利能力显著改善。这背后，既有国家政策的持续引导、资本市场信心的回暖，也离不开企业自身研发实力的跃升。在这些积极因素共振下，创新药行业的经营状况和市场价值有望继续同步提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817302532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","BK1574","LNGR","BK1161","159992","MEDX","IPOS","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653747734","title":"研报掘金丨华源证券：首予众生药业“买入”评级，进入创新药价值兑现关键阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2653747734","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653747734?lang=zh_cn&edition=full","pubTime":"2026-07-22 14:34","pubTimestamp":1784702084,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","161027","159992","BK0077","002317","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653734695","title":"英硅智能(03696)最高涨8% AI创新药龙头迎来板块情绪催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2653734695","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653734695?lang=zh_cn&edition=full","pubTime":"2026-07-22 14:05","pubTimestamp":1784700315,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英硅智能 早盘震荡冲高，最高触及47.94港元，涨幅超8%，最新报46.24港元，涨幅4.52%，成交额4.62亿港元。其他消息上，市场分析表示，港股生物医药板块整体回暖，AI制药赛道热度回升。多家机构看好AI制药长期发展前景，随着公司核心管线逐步进入关键临床节点，后续临床数据有望持续带来估值催化。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986496","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTHR","IBBQ","BK1574","LNGR","03696","AIPO","BK1161","159992","CHAT","MEDX","BK1141","QTOC","06978","ARTY","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653781736","title":"创新药板块早盘冲高回落，港股通创新药ETF易方达（159316）连续4日“吸金”累计超3.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653781736","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653781736?lang=zh_cn&edition=full","pubTime":"2026-07-22 13:08","pubTimestamp":1784696900,"startTime":"0","endTime":"0","summary":"今日早盘，创新药板块冲高回落，截至午间收盘，恒生港股通创新药指数上涨1.0%，中证港股通医药卫生综合指数上涨0.6%，中证创新药产业指数上涨0.3%，中证生物科技主题指数下跌0.1%，沪深300医药卫生指数上涨0.3%。同花顺iFinD数据显示，港股通创新药ETF易方达(159316，联接基金A/C：024328/024329)已连续4日获资金净流入，合计超3.5亿元。天风证券认为，在国内BD交易潮、创新药研发需求持续火热的情况下，国内需求有望持续高增长，有望带动创新药产业链整体板块业绩高增速，可关注大单品放量及相应机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026072200025105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","06978","BK1574","159316","516080","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653817477","title":"创新药主题基金总规模突破1500亿元；张坤最新调仓动向曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2653817477","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653817477?lang=zh_cn&edition=full","pubTime":"2026-07-22 08:01","pubTimestamp":1784678484,"startTime":"0","endTime":"0","summary":"｜2026年7月22日星期三｜NO.1兴业基金李辉离任总经理7月21日，兴业基金公告，李辉因个人原因，于7月20日离任总经理，董事长刘宗治代任总经理职务。据悉，2023年6月胡斌离职之后，同年9月公司聘任国泰基金原副总经理李辉担任总经理一职。李辉具备保险、银行、公募跨业工作经验，属于典型的职业经理人，并非出自银行系统。此外，兴业基金还公告，黄文锋因年龄原因，离任公司副总经理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223816306091.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223816306091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","159992","IBBQ","BK1574","BK1161","06978","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653973270","title":"沃华医药：目前暂未有创新药项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2653973270","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653973270?lang=zh_cn&edition=full","pubTime":"2026-07-21 20:51","pubTimestamp":1784638286,"startTime":"0","endTime":"0","summary":"证券之星消息，沃华医药(002107)07月20日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司有创新药项目吗?沃华医药回复：尊敬的投资者您好！公司目前聚焦于心脑血管、骨骼肌肉、代谢健康等慢病领域的中成药研发，不排除在条件、时机成熟时通过新产品收购或资本运营方式获得与现有产品线形成协同效应的新产品。目前暂未有创新药项目。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100042280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","06978","BK1161","002107","BK0239","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653273144","title":"公司问答丨海南海药：创新药氟非尼酮III期已制定研发进度计划 目前已开始III期临床相关前期工作 派恩加滨IIb期正积极推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2653273144","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653273144?lang=zh_cn&edition=full","pubTime":"2026-07-21 17:40","pubTimestamp":1784626804,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","159992","BK0070","BK0146","BK0060","000566","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653733442","title":"葛兰旗下中欧医疗健康混合二季报：君实生物(688180.SH)新进十大重仓 创新药及产业链仍是布局主要方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2653733442","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653733442?lang=zh_cn&edition=full","pubTime":"2026-07-21 17:16","pubTimestamp":1784625396,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月21日，中欧基金披露葛兰和赵磊共同管理的中欧医疗健康混合型证券投资基金2026年第2季度报告。此外，君实生物新进持仓前十，信立泰跌出十大重仓。葛兰在季报中指出，2026年第二季度，市场风格分化显著，医药生物板块经历大幅震荡，整体走势弱于大盘。葛兰表示，第三季度创新药及产业链仍是布局的主要方向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","BK1161","BK4588","06978","BK0239","VHT","BK1583","IXJ","MEDX","01877","BK4550","688180","BK1515","159760","IBBQ","BK4585","LABU","XLV","XBI","BK1574","LNGR","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653916221","title":"又下一城！鸿鹄航空构建创新药全球温控中国方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2653916221","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653916221?lang=zh_cn&edition=full","pubTime":"2026-07-21 14:40","pubTimestamp":1784616042,"startTime":"0","endTime":"0","summary":"近日，鸿鹄航空科技与沙特航空正式签署主动航空温控集装箱租赁协议，这家成立仅四年多的中国企业，在中东落下了全球网络的又一枚关键棋子。中国目前已是全球第二大创新药研发大国，但中国创新药的全球化流通，长期依赖海外温控物流服务体系。鸿鹄的出现，正在改变这一格局——以自主技术突破为起点，以全球航司合作为纽带，以核心城市站点为节点，构建起一套属于中国创新药的全球温控流通方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.stockstar.com/SS2026072100022685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","02252","BK1574","159231","BK1161","BK1617","159992","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653216832","title":"创新药物销售强劲抵消仿制药冲击！诺华制药Q2业绩超预期 释放重回增长轨道信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2653216832","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653216832?lang=zh_cn&edition=full","pubTime":"2026-07-21 14:28","pubTimestamp":1784615333,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华制药公布了好于市场预期的第二季度业绩。新一代抗癌药物的强劲表现抵消了重磅心脏药物Entresto遭遇仿制药冲击带来的影响，释放出公司重回增长轨道的信号。销售额增长主要由一系列创新药物推动。诺华制药预计将公布多项实验性疗法的重要临床试验结果，涵盖心脏病和多发性硬化症等领域。其中包括治疗肌肉疾病的首款药物Del-desiran，该药物靶向相关肌肉疾病的遗传病因，来自诺华制药以120亿美元收购Avidity Biosciences所获得的产品管线。","market":"us","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470258.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LNGR","IE0009355771.USD","BK4588","BK1191","BK1574","LU0320765489.SGD","NVS","IE00BFTCPJ56.SGD","LU0211331839.USD","IE00B4R5TH58.HKD","BK4007","IE00BJJMRZ35.SGD","LU0070302665.USD","159992","PPH","BK4578","BK1161","IE00BJT1NW94.SGD","MEDX","IE00B2B36J28.USD","BK4532","LU0208291251.USD","IE0002141913.USD","IBBQ","BK4585"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2653269226","title":"出海爆发+投融资回暖+业绩预增！恒生创新药ETF华泰柏瑞（520500）T+0助力把握低估值创新药反弹机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2653269226","media":"新浪基金","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653269226?lang=zh_cn&edition=full","pubTime":"2026-07-21 13:43","pubTimestamp":1784612580,"startTime":"0","endTime":"0","summary":"近期，前期涨幅较大的科技板块迎来明显回调，市场波动有所放大。与之相对，创新药板块自上一轮调整后，估值仍处于历史低位区间——截至2026年7月20日，恒生创新药指数最新市盈率为43.70倍，处于近五年31.96%的分位水平。随着创新药BD出海、投融资回暖、前沿突破、头部药企释放盈利信号和密集回购等多重利好因素共振，该板块自2026年6月底以来逐步走出反弹行情，相关ETF交投活跃。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-07-21/doc-iniipxxh8087536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159992","LNGR","IBBQ","BK1574","MEDX","06978","520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652152322","title":"Halozyme(HALO)与Incyte(INCY)联合推进创新药INCA033989皮下注射剂型开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652152322","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652152322?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:59","pubTimestamp":1784552369,"startTime":"0","endTime":"0","summary":"双方将利用Halozyme专有的ENHANZE药物递送技术，共同推进Incyte旗下在研创新药INCA033989皮下注射剂型的开发。根据协议条款，Halozyme将从Incyte获得一笔首付款，并有资格在未来达成特定开发及商业化里程碑时获得追加付款。此外，Halozyme还将根据使用ENHANZE技术药物的未来净销售额抽取一定比例的特许权使用费。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/N2FmNjkyMzgyNTQ0NjcyNTYzMw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/N2FmNjkyMzgyNTQ0NjcyNTYzMw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INCY","BK1161","IDNA","HALO","159992","MEDX","LU0053671581.USD","IBBQ","BK4550","BK4585","06978","BK1574","BK4532","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652213076","title":"睿远成长价值混合基金披露二季报：减持PCB、芯片和光通信板块 港股配置以消费和创新药为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2652213076","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652213076?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:22","pubTimestamp":1784550162,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，由傅鹏博和朱璘管理的睿远成长价值混合基金披露2026年二季报。截至2026年二季度末，睿远成长价值混合基金的资产净值为222.01亿元，较一季度末时的181.56亿元增长40.45亿元。配置以消费和创新药个股为主，二季度以来其表现一般，经历调整后，近期创新药子板块有些许企稳向上的迹象。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0143863198.USD","LU0823414551.USD","BK0214","LU1146622755.USD","LU2041044095.USD","LU1868838027.USD","LU2092937221.SGD","IE0008368742.USD","LU2294711713.HKD","BK0132","LU2097828474.EUR","BK0072","LU0345770308.USD","LU0312595415.SGD","LU1868837565.USD","LU0244354667.USD","LU2238339852.HKD","LU0516422440.USD","LU0039217434.USD","LU0082770016.SGD","SG9999011746.SGD","LU1961090484.USD","300751","LU0456827905.SGD","LU0823426480.USD","LU0561508036.HKD","IE00BMPRXQ63.HKD","LU0327786744.USD","IE0032431581.USD","LU1023057109.AUD","LU0593848301.USD","LU0611395673.USD","LU1242518931.SGD","LU2477742899.HKD","LU0823414478.USD","LU0231483743.USD","LU0106252389.USD","IE00B8L5B284.USD","LU0620787316.HKD","LU1051769294.HKD","LU1770034418.SGD","LU0634319403.HKD","LU2476274308.USD","LU1328277881.USD","LU0463099449.HKD","LU0784639295.USD","LU0871576103.HKD","LU0314109678.HKD","BK0012","LU0072462343.USD","LU0509642566.USD","LU1102505762.USD","LU0359201885.HKD","688167","LU0650527681.SGD","LU0047713382.USD","BK0102","LU0505663152.USD","LU2360107325.USD","LU0254981946.USD","LU2177674079.SGD","HK0000306701.USD","LU0370786039.SGD","LU1255011170.USD","LIT","LU1051768304.USD","LU0181495838.USD","HK0000151867.HKD","LU0828237510.HKD","LU0651946864.USD","LU2360108059.USD","LU0708995583.HKD","LU0117844026.USD","HK0000181138.USD","LU1794554557.SGD","BK0064","LU0124384867.USD","IE00BYQNZ168.SGD","LU0455707207.USD","LU2023250504.SGD","LU0072913022.USD","LU0531971595.HKD","LU0449515922.USD","LU0188438112.USD","LU2399975544.HKD","LU0128522157.USD","BK0148","LU0320764755.SGD","300308","BK0187","SGXZ49509284.SGD","LU0572940350.SGD","LU0067412154.USD","LU2152927971.USD","LU1997244956.HKD","LU0320764599.SGD","LU1880383440.USD","LU2449936058.SGD","LU2348773727.SGD","LU1917777945.USD","LU0880133367.SGD","SG9999001226.SGD","LU0264606111.USD","LU0302445910.USD","LU0210526637.USD","300476","LU1781817850.SGD","LU1974910355.USD","LU0043850808.USD","LU0106959298.USD","LU2242644610.SGD","LU0326950275.SGD","BK0197","002444","LU1808992512.USD","LU0214875030.USD","LU1979443071.USD","LU1655091616.SGD","LU0048388663.USD","LU1188198961.HKD","LU1831875114.USD","LU0266013472.USD","LU1769817096.USD","LU0251143458.SGD","LU0572944931.SGD","LU2289578879.USD","LU2039709279.SGD","LU1048596156.SGD","LU0501845795.SGD","LU1048588211.SGD","LU0516422952.EUR","LU0051755006.USD","SG9999001846.SGD","LU0449509016.USD","BK0141","LU0132412106.USD","LU0165289439.USD","LU0048580855.USD","IE00B12V2V27.USD","LU0048575426.USD","LU2580892789.USD","LU1515016050.SGD","IE00BZ199S13.USD","LU2506952337.HKD","LU0049853897.USD","BK0183","LU0828237940.HKD","SG9999000327.SGD","LU0348827113.USD","IE00BMPRXR70.SGD","LU0106259558.USD","SG9999001903.USD","LU1655091459.SGD","LU2097828805.USD","002008","LU0029875118.USD","300750","LU0531970944.HKD","SG9999003461.SGD","LU0345770993.USD","IE00B543WZ88.USD","LU0516423174.USD","LU1152091754.HKD","LU1807302812.USD","LU0469268626.HKD","LU2424517915.HKD","LU0516423091.SGD","LU0328353924.USD","LU0898667661.SGD","LU0417516738.SGD","LU2097828714.EUR","IE00B8HQ1Z84.USD","LU1720050803.USD","LU0259732245.USD","LU0164939612.USD","LU1820825898.SGD","300502","LU1721428347.USD","02475","IE00BYTNYN87.SGD","LU0164872284.USD","LU0516422366.SGD","LU2328871848.SGD","LU0823437842.USD","BK0109","IE00BMPRXN33.USD","LU0405327148.USD","LU2476274720.SGD","LU1997245177.USD","LU0359201612.USD","LU0054450605.USD","IE0034224299.USD","002475","LU3063872942.SGD","LU0261950470.USD","02476","LU0724618433.USD","SG9999002828.SGD","LU1993786604.SGD","LU2249611893.SGD","LU1960683339.HKD","LU0326948709.USD","EVS.SI","IE00BPRC5H50.USD","LU0143863784.USD","LU2148510915.USD","LU0052750758.USD","IE0003795394.USD","LU0502904849.HKD","BK0073","IE00BD6J9T35.USD","BK0196","LU2298322129.HKD","LU0540923850.HKD","LU2298064838.USD","LU1008478684.HKD","LU1813983027.USD","LU0417516902.SGD","LU1978683503.SGD","BK0167","LU1939255532.USD","BK0201","LU0192582467.USD","LU0979878070.USD","IE0003851619.USD","159992","LU0082770016.USD","LU2778985437.USD","BK0028","IE00B031HY20.USD","LU0228659784.USD","LU1064130708.USD","LU1303224171.USD","HK0000181112.HKD","LU1719994722.HKD","LU0607220059.USD","LU2294711473.HKD","BK0256","LU0672654166.SGD","LU2125910500.SGD","IE00B5MMRT66.SGD","SG9999001689.USD","SGXZ81163826.USD","BK0251","LU1064131003.USD","LU0348805143.USD","LU0140636845.USD","LU1861219969.SGD","LU0651947912.USD","LU0823413587.USD","LU0011963245.USD","LU2506952253.HKD","LU1152091168.USD","LU0405327494.USD","LU1969619763.USD","LU1102505929.USD","LU1039395188.USD","LU2097828631.EUR","LU2153591404.USD","CXSE","LU2275660780.HKD","HK0000306685.HKD","LU0269904917.USD","LU0594300419.USD","LU1251922891.USD","LU1934453819.USD","LU2106854487.HKD","LU0831103253.SGD","LU2357125470.USD","LU2008162690.USD","HK0000320264.USD","IE00B0JY6N72.USD","LU2045819591.USD","LU0543330483.HKD","LU2580892862.HKD","LU2506952410.USD","002384","LU0235996351.USD","LU2298321311.HKD","BK0061","LU0210527791.USD","LU0348825331.USD","BK0077","IE00B3M56506.USD","LU0164865239.USD","LU2125910849.SGD","LU0828238088.HKD","LU0605514214.HKD","LU0821914370.USD","LU0823426308.USD","LU0594300179.USD","LU1769817179.HKD","LU0149534421.HKD","LU2495084118.USD","LU1997245094.SGD","HK0000320223.HKD","BK0152","BK0076","LU2097828557.USD","LU2394011477.USD","LU1880383366.USD","SG9999000459.SGD","LU1580142542.USD","BK0224","LU0107464264.USD","IE00B29SXG58.USD","LU2506951792.HKD","03750","LU2213484517.USD","LU1242518857.USD","LU2348774022.SGD","SG9999002463.SGD","BK0188","LU1861214812.USD","LU0348735423.USD","LU0359202008.SGD","LU0572939691.SGD","LU2153592121.USD","LU0823413660.USD","BK0070","BK0171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652213427","title":"创新药板块走强，半导体板块延续调整，科创50ETF易方达（588080）近5日“吸金”超30亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652213427","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652213427?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:18","pubTimestamp":1784549939,"startTime":"0","endTime":"0","summary":"截至收盘，科创50指数上涨0.2%，科创综指下跌2.3%，科创100指数下跌4.4%，科创200指数下跌6.2%。盘面上，半导体板块多数下跌，创新药板块上涨，益方生物涨超15%，艾力斯涨超11%，百利天恒、迈威生物涨超7%，亚虹医药涨逾6%。同花顺iFinD数据显示，截至7月17日，科创50ETF易方达(588080，联接基金A/C/Y：011608/011609/022895)近5日净流入达31亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026072000035708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1161","588080","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652290964","title":"创新药火速修复，520880成反弹急先锋！场内唯一药ETF8天7涨！映恩生物、艾力斯、荣昌生物等多股释放利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2652290964","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652290964?lang=zh_cn&edition=full","pubTime":"2026-07-20 19:19","pubTimestamp":1784546340,"startTime":"0","endTime":"0","summary":"周一，AH医药资产经历上周“黑色星期五”后率先迎来修复。港股通医药弹性十足，港股通创新药ETF华宝、港股通医疗ETF华宝大涨4.17%、3.27%。A股医药逆市活跃，药ETF华宝、医疗ETF华宝携手反弹2.5%。 港股通创新药全天强势，100%创新药研发标的——520880盘中一度上探4.63%，放量成交8.1亿元。 A股制药板块同步反弹，场内唯一跟踪制药指数的药ETF华宝低开后直线拉升翻红，盘中冲高3%，收涨2.58%走出“8天7涨”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-07-20/doc-iniinfqe4980267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688578","09995","LU1969619763.USD","BK1583","MEDX","LU2488822045.USD","LU2148510915.USD","520880","IBBQ","159992","688331","LU2328871848.SGD","06978","BK1161","BK0239","LU1064130708.USD","BK1574","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652998332","title":"申联生物：在研创新药具备差异化竞争优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2652998332","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652998332?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:48","pubTimestamp":1784537303,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物07月20日在投资者关系平台上答复投资者关心的问题。公司研发的几款创新药是不是没有市场竞争力？最近一个月创新药都是大涨的，其中很多翻倍的。而申联在其他创新药企业大涨时它反而下跌，其他创新药企业下跌时它暴跌申联生物回复：感谢您对公司的关注。二级市场股价波动受宏观经济环境、市场资金等多重因素影响。公司经营稳健，各项业务有序推进，在研创新药具备差异化竞争优势，目前临床进展符合既定预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000025140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","BK1161","06978","688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652269822","title":"创新药板块活跃 荣昌生物(09995)涨7.28% 多支头部公募大举举牌港股创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652269822","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652269822?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:26","pubTimestamp":1784514372,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块活跃，荣昌生物 涨7.28%，歌礼制药-B涨6.81%，科伦博泰生物涨6.70%，康诺亚-B涨6.25%，康方生物涨5.83%，药明合联涨5.53%，石药集团涨4.94%，三生制药涨5.02%，信达生物涨4.55%，药明生物涨4.60%，恒瑞医药涨4.00%，百济神州涨3.88%。头部机构密集触及举牌线，凸显对创新药板块的看好。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986240","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2399975544.HKD","LU0516422366.SGD","LU0348735423.USD","HK0000165453.HKD","LU0043850808.USD","06160","LU0359201612.USD","01093","LU0979878070.USD","LU2097828474.EUR","BK1593","IBBQ","LU0052750758.USD","09995","KURE","LU1226288170.HKD","LU0348827113.USD","LU0516422440.USD","LU0708995583.HKD","BK4585","06978","01530","01276","BK1576","LU0417516738.SGD","LU0516423174.USD","09926","MEDX","BK1588","LU1720050803.USD","02269","LU1951186391.HKD","SG9999002463.SGD","01672","BK0239","688331","IE00BZ08YT58.USD","LU0327786744.USD","LU2328871848.SGD","KCAI","VXUS","LU1064130708.USD","01801","02268","LU0196878994.USD","LU1242518857.USD","02162","159992","06990","LU1242518931.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652266796","title":"基金忠言｜富国和易方达双双出手，捕捉创新药大牛股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652266796","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652266796?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:18","pubTimestamp":1784513897,"startTime":"0","endTime":"0","summary":"7月中旬以来，创新药板块强劲反弹，涨幅一度达30%左右。市场的短期波动，并不影响头部基金公司在创新药板块的战略性布局。据香港交易所信息，7月2日、7日，易方达、富国因增持百奥赛图H股，两家各自持股比例先后突破7%。易方达医疗保健行业也在今年一季度把百奥赛图纳入前十大重仓股，位列第五位。三是对于希望能跑赢中证创新药指数，获取超额收益的投资者，可以考虑富国和易方达的主动型创新药基金。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1784512731516724474","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IBBQ","06978","BK1574","MEDX","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784760507800,"stockEarnings":[{"period":"1week","weight":-0.0351},{"period":"1month","weight":0.1844},{"period":"3month","weight":0.0628},{"period":"6month","weight":0.0209},{"period":"1year","weight":0.0069},{"period":"ytd","weight":0.059}],"compareEarnings":[{"period":"1week","weight":-0.0224},{"period":"1month","weight":-0.0711},{"period":"3month","weight":-0.0553},{"period":"6month","weight":-0.0651},{"period":"1year","weight":0.0796},{"period":"ytd","weight":-0.0257}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}